Report of Foreign Issuer (6-k)
06 August 2018 - 9:44PM
Edgar (US Regulatory)
Securities
and Exchange Commission
w
ashington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of
|
August
|
|
2018
|
Commission File Number
|
001-36458
|
|
|
Neovasc
Inc.
|
(Translation of registrant’s name into English)
|
Suite 5138 - 13562 Maycrest Way
Richmond, British Columbia, Canada, V6V 2J7
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document
|
|
|
|
|
|
Document 1
|
|
News Release dated August 6, 2018 - Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference
|
|
|
|
DOCUMENT 1
Neovasc to Present at the 38th Annual
Canaccord Genuity Growth Conference
NASDAQ, TSX: NVCN
VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc,
Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive
transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of
Neovasc, is scheduled to present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8
th
at
12:30 pm ET being held in Boston, Massachusetts.
A live audio webcast of the presentation will
be available on the Investors page of Neovasc's website at www.neovasc.com.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina,
which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and
the Tiara™ (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical
investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
View
original content:http://www.prnewswire.com/news-releases/neovasc-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-300692129.html
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/August2018/06/c4117.html
%CIK: 0001399708
For further information:
Chris Clark, Chief Financial Officer,
Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568
CO: Neovasc Inc.
CNW 07:20e 06-AUG-18
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Neovasc
Inc.
|
|
(Registrant)
|
Date:
|
|
August 6, 2018
|
|
By:
|
/s/
Chris Clark
|
|
Name: Chris Clark
Title: Chief Financial Officer
|
|
|
|
|
|
|
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024